Hendley & Co. Inc. Buys Shares of 1,179 Amgen Inc. (NASDAQ:AMGN)

Hendley & Co. Inc. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,179 shares of the medical research company’s stock, valued at approximately $368,000.

Other large investors have also recently bought and sold shares of the company. Horizon Financial Services LLC acquired a new stake in shares of Amgen in the first quarter valued at about $28,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen in the 4th quarter valued at approximately $29,000. United Community Bank bought a new position in Amgen in the 4th quarter worth approximately $29,000. Delos Wealth Advisors LLC lifted its holdings in shares of Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the last quarter. Finally, Bbjs Financial Advisors LLC bought a new stake in shares of Amgen in the second quarter valued at approximately $33,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 0.2 %

Shares of NASDAQ:AMGN traded down $0.72 during trading on Wednesday, hitting $322.73. 1,630,371 shares of the company’s stock traded hands, compared to its average volume of 2,628,244. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The company has a 50-day moving average price of $318.96 and a 200-day moving average price of $298.94. Amgen Inc. has a 52 week low of $248.38 and a 52 week high of $346.85. The company has a market cap of $173.12 billion, a price-to-earnings ratio of 46.21, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same quarter in the previous year, the business earned $5.00 earnings per share. The company’s revenue was up 20.1% on a year-over-year basis. As a group, research analysts forecast that Amgen Inc. will post 19.5 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Friday, August 16th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.79%. The ex-dividend date is Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AMGN shares. Bank of America boosted their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $230.00 to $300.00 in a report on Friday, May 3rd. BMO Capital Markets lifted their target price on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Argus increased their price target on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Eleven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $326.89.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.